Table 1.
Patterns of new onset adverse skin reactions associated with SARS-CoV-2 vaccinations.
| Pattern | Subtype | Reported Associated Vaccines |
|---|---|---|
| Injection site reactions | Immediate local reaction | All |
| Delayed local reaction | ||
| Filler reactions | - | Pfizer/BioNTech, Moderna |
| Exanthemas | Erythematous confluent | All |
| Maculopapular | ||
| Papulovesicular | ||
| Pityriasis rosea like | Pfizer/BioNTech, Moderna, AstraZeneca/Oxford | |
| SDRIFE | Pfizer/BioNTech | |
| Annular | Johnson & Johnson/Janssen | |
| Vascular lesions | Leucocytoclasic vasculitis | All |
| Urticarial vasculitis | Pfizer/BioNTech | |
| Purpura/petechiae | All | |
| Livedo racemosa | Pfizer/BioNTech | |
| Chilblain-like | Pfizer/BioNTech, Moderna | |
| Erythromelalgia | Pfizer/BioNTech, Moderna | |
| Urticaria | Wheals and/or angioedema | Pfizer/BioNTech, Moderna, AstraZeneca/Oxford |
| Eczematous dermatitis | - | Pfizer/BioNTech, Moderna |
| Autoimmune bullous reactions | Subepidermal bullous diseases | Pfizer/BioNTech, Moderna |
| Pemphigus | Pfizer/BioNTech | |
| SCARs | AGEP | AstraZeneca/Oxford |
| DRESS | Johnson & Johnson/Janssen | |
| SJS/TEN | Pfizer/BioNTech, AstraZeneca/Oxford | |
| EM major | Moderna | |
| Extensive FDE | Moderna | |
| Other dermatoses | Sweet syndrome | Moderna |
| Rosacea-like eruption | Pfizer/BioNTech, Johnson & Johnson/Janssen | |
| Psoriasis (plaque, guttate, palmoplantar, and generalized pustular) | Pfizer/BioNTech, Moderna, Johnson & Johnson/Janssen | |
| Pityriasis rubra pilaris-like eruption | Pfizer/BioNTech |
SDRIFE: Symmetrical Drug-related Intertriginous and Flexural Exanthema; SCARs: Severe cutaneous adverse reactions; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; AGEP: acute generalized exanthematous pustulosis; DRESS: drug reaction with eosinophilia and systemic symptoms; FDE: fixed drug eruption; EM: erythema multiforme.